Palisade Bio Inc (PALI) Stock Price

2.20 ▲ +0.11 (+5.26%)
Open: 2.09 Vol: 3.53M Day's range: 2.08 - 2.235 Sep 08, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
PALI Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 2.19▲ 2.20▼ 2.20▼ 2.06▲ 2.11▲
MA10 2.19▲ 2.20▼ 2.16▲ 2.05▲ 2.04▲
MA20 2.19▲ 2.15▲ 2.10▲ 2.07▲ 1.97▲
MA50 2.20▼ 2.07▲ 2.03▲ 2.03▲ 1.93▲
MA100 2.16▲ 2.04▲ 2.06▲ 2.00▲ 1.58▲
MA200 2.10▲ 2.06▲ 2.06▲ 1.95▲ 9.21▼
  5 mins 30 mins Hourly Daily Weekly
MACD 0.000▼ -0.001▼ 0.011▲ 0.004▲ 0.011▲
RSI 51.603▲ 62.966▲ 71.622▲ 58.886▲ 57.142▲
STOCH 59.167     57.828     81.700▲ 45.037     67.350    
WILL %R -20.000▲ -25.806     -19.512▲ -10.937▲ -13.846▲
CCI 178.947▲ 32.119     70.262     138.467▲ 123.036▲
Latest Filters Detected On PALI
▲ PSAR&MOM $PALI PSAR Switch Up + Momentum Set Alert
▲ RSI&MACD $PALI MACD cross and RSI above 55 Set Alert
▲ MACD $PALI MACD(12,26,9) Crossed Above Signal Line Set Alert
▲ BREAK $PALI Price Breaks 10 Days High Set Alert
Palisade Bio Inc News
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Monday, August 10, 2026 09:20 AM
Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first ...
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
Monday, June 29, 2026 05:30 AM
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; ...
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
Thursday, June 11, 2026 05:45 AM
Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones Denver, CO, June 11, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.
PALI historical stock data
date open high low close volume
08/09/26 2.09 2.235 2.08 2.20 3,527,909
04/09/26 2.03 2.12 2.00 2.09 1,754,735
03/09/26 2.01 2.05 1.97 2.045 1,086,450
02/09/26 1.96 2.005 1.95 1.99 730,430
01/09/26 1.96 1.98 1.915 1.96 879,445
31/08/26 2.02 2.02 1.93 1.95 1,644,457
28/08/26 2.10 2.1116 1.99 2.00 2,127,082
27/08/26 2.12 2.16 2.095 2.11 899,068
26/08/26 2.06 2.135 2.032 2.13 1,190,105
25/08/26 2.05 2.10 1.98 2.07 2,067,764
Quote Details
52wk Low:0.547
52wk High:2.855
Vol:3.53M
Avg Vol(3m):35.3M
1Y Chng:+221.45%
1M Chng:+8.91%
Add to Watch List
More Information
Index US Composite
Market Cap. 364.23M